SuperworthBicycle Therapeutics BCYC
- Market cap
- $248.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $61.2M
- +217% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −83.8%
Bicycle Therapeutics trades at 4.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $61.2M over the last twelve months, up 217% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.4M+76% | $5.3M+67% | $19.5M+299% | $9.4M−18% | $2.7M−50% | $3.7M−30% | $10M−49% | $2.9M−69% | $11.7M+339% | $48M+1193% | $887K−91% | $629K−79% | |
| R&D | $39.9M+75% | $44.7M+81% | $34.9M+8% | $40.1M+1% | $48.3M+21% | $49.8M+11% | $59.1M+69% | $71M+77% | $58.4M+21% | $51.8M+4% | $48.9M−17% | $41.2M−42% |
| SG&A | $16.3M+62% | $14.9M+39% | $16.4M+13% | $15.9M+8% | $18.3M+12% | $21.6M+45% | $21.1M+29% | $18.5M+16% | $18.9M+3% | $20.9M−3% | $17.5M−17% | $14M−24% |
| −$50.8M+71% | −$54.2M+68% | −$31.7M−24% | −$46.6M+8% | −$63.8M+26% | −$67.7M+25% | −$70.2M+121% | −$86.6M+86% | −$65.6M+3% | −$24.7M−64% | −$65.5M−7% | −$54.6M−37% | |
| Interest expense | $814K−0% | $820K−1% | $821K+2% | $824K+0% | $33K−96% | $52K−94% | $51K−94% | $54K−93% | $44K+33% | $57K+10% | $48K−6% | $44K−19% |
| Pre-tax income | −$47.6M+67% | −$48.8M+61% | −$26.9M−32% | −$39.7M−8% | −$54.3M+14% | −$52.9M+9% | −$61.8M+130% | −$79.2M+100% | −$58.9M+9% | −$18.9M−64% | −$60.7M−2% | −$50.2M−37% |
| $2.3M | $320K | −$350K−43% | $115K | −$3.4M | −$1.1M | −$1.1M+211% | −$231K | $205K | $1.3M | $172K | $90K | |
| Net income | −$49.9M+76% | −$49.1M+64% | −$26.6M−32% | −$39.8M−7% | −$50.8M+2% | −$51.9M+6% | −$60.8M+129% | −$79M+98% | −$59.1M+16% | −$20.2M−61% | −$60.8M+0% | −$50.3M−36% |
| −$1.26+31% | −$1.16+15% | −$0.62−52% | −$0.77−45% | −$0.74−41% | −$0.75−35% | −$0.88+42% | −$1.14+48% | −$0.85+15% | −$0.29−61% | −$0.87−1% | −$0.72−37% | |
| 39.6M+33% | 42.4M+43% | 42.6M+42% | 52M+72% | 69M+74% | 69.1M+63% | 69.2M+63% | 69.3M+33% | 69.3M+1% | 69.4M+1% | 69.7M+1% | 69.8M+1% |
Revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
R&D: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Income tax: Q1 FY19: 6 months less the 3 months printed beside them.
Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 6 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Bicycle Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BCYCBicycle Therapeutics | $248.5M | n/m | n/a | 4.1× | +217% | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| Peer median | $570.3M | 11.3× | 13.6× | 1.4× | +7% | 13.6% |
More on Bicycle Therapeutics
Each number over time
Where it ranks
- #4of 341Healthcare stocks with the fastest revenue growth
- #3of 97Large drugmakers with the fastest revenue growth
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .